2 not yet recruiting, 2 unknown, 1 recruiting. 3 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Yunpeng Liu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer SHR-A1811 & Apartinib - Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Yunpeng Liu | 28 | 2024-12-01 | 2024-10-30 |
| Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin - Small Cell Lung Cancer | Not applicable | Recruiting | Yunpeng Liu | 38 | 2024-08-09 | 2025-01-06 |
| Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma irinotecan hydrochloride liposome injection, Capecitabine, Lenvatinib - Biliary Tract Carcinoma | Not applicable | Not yet recruiting | Yunpeng Liu | 30 | 2024-07-01 | 2024-06-18 |
| The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy Thalidomide, Dexamethasone, 5-HT3 antagonists - Chemotherapy-induced Nausea and Vomiting | Not applicable | Unknown | Yunpeng Liu | 880 | 2018-07-12 | 2018-07-26 |
| Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic temozolomide - Extensive Stage Small Cell Lung Cancer | Phase 2 | Unknown | Yunpeng Liu | 60 | 2016-06-01 | 2016-11-23 |
Small Cell Lung Carcinoma (1) · Vomiting (1)
Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Dexamethasone (1) · Etoposide (1) · Palonosetron (1) · Serotonin 5-HT3 Receptor Antagonists (1) · Temozolomide (1) · Thalidomide (1) · apatinib (1) · lenvatinib (1)
China (5)
Xiujuan Qu (2)